KESTRA MEDICAL TECHNOLOGIES Q1 FY27 earnings call KMTS

Kestra's integrated care model, featuring the Assure WCD system and Heart Alert Services, demonstrated its differentiated value this quarter. A patient prescribed the Assure WCD experienced over 120 diverted therapies in one night, prompting immediate outreach. Heart Alert Services coordinated care, sending clinical reports ahead and ensuring the patient received urgent specialized treatment, including an airlift to a Las Vegas hospital for a successful lead extraction and device replacement. This case highlights the platform's therapeutic protection, clinical insight, and responsive support.

The company is implementing a disciplined AI roadmap, firmly grounded in measurable business outcomes to improve growth, efficiency, or scalability. Initial priorities include AI-powered patient support and automated outreach to enhance engagement and wear compliance, automation of intake and prior authorization workflows to improve fittings-to-claim conversion and collections, and AI assistance for sales representatives in call preparation, follow-up, and account prioritization to increase rep productivity without proportional headcount growth. These initiatives leverage Kestra's foundational technology stack to bend the operating expense curve.

Kestra's commercial organization is successfully gaining market share and expanding the WCD market. New sales representatives are ramping faster than prior cohorts due to investments in recruiting and training. In high-volume markets, the company is strategically splitting territories and adding clinical account specialists, which compounds growth by increasing feet on the ground and leading to deeper account penetration. This model drives higher territory manager productivity and operating leverage, positioning Kestra to capitalize on the underpenetrated WCD category.

Despite overwhelming evidence, WCD therapy remains underutilized, with 6 out of 7 indicated patients unprotected in 2025. Kestra's innovation and clinical evidence are beginning to change this, contributing to a WCD market growth of approximately 14% on a dollar basis in the 12 months ended July 2026. Management believes the company is in the early innings of market expansion and sees the category growing into a multi-billion dollar market in the years ahead, with Kestra currently holding about 15% market share in the U.S.

Kestra continues to expand its market access, increasing its in-network patient mix to the low 80s from 70% at the time of its IPO 18 months ago. The company was added to the Federal Supply Schedule for the U.S. Department of Veterans Affairs, seeing a steady increase in volumes. Notably, a significant national payer recently expanded coverage to non-ischemic patients undergoing guideline-directed medical therapy, a first for this payer, signaling that recent clinical evidence is influencing payer policies for WCDs, especially given that over 60% of the typical WCD population is non-ischemic.

Innovation remains a core focus and investment area. Kestra is progressing with its Biobeat Technologies partnership to integrate noninvasive blood pressure monitoring into the Assure platform. Additionally, the company is completing an exciting late-stage R&D project designed to further extend the Assure System's clinical advantage and introduce new first-in-category capabilities to the market, with further details expected next quarter. These innovations are anticipated to accelerate market growth and differentiate Kestra's product.

Kestra delivered strong financial performance in Q1 FY27, with 60% revenue growth and significant gross margin expansion. The company fortified its balance sheet with a new $200 million term loan facility, resulting in $245 million in cash, cash equivalents, and investments as of July 31, and approximately $320 million in total liquidity. Management is confident in its path to profitability over the next few years, driven by continued investments in commercial strategies, RCM capabilities, and R&D initiatives, positioning Kestra for durable, best-in-class growth.